In patients with moderate CKD, diminished activity levels of the antioxidant HDL‐associated enzyme PON‐1, as monitored by serum arylesterase and PON activities, predict increased risk for the development of adverse cardiac events, including nonfatal myocardial infarction, nonfatal stroke, or death, in multivariable models adjusted for established clinical and biochemical risk factors. The gene discussed is PON1; the disease is myocardial infarction.